FDA
-
-
-
-
-
-
-
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
-
-
-
-
-
-
-
KPTI phase 3 myelofibrosis trial selected for ASCO presentation
-
-
-
-
-
-
-
Karyopharm raises $30 million in private placement with RA Capital
-
-
-
-
-
-
-
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
-
-
-
-
-
-
-
Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis
-
-
-
-
-
-
-
Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress
-
-
-
-
-
-
-
Karyopharm Therapeutics (KPTI) PT Raised to $5 at Piper Sandler
-
327,204 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

